TY - JOUR
T1 - Functional crosstalk between T cells and monocytes in cancer and atherosclerosis
AU - Padgett, Lindsey E.
AU - Araujo, Daniel J.
AU - Hedrick, Catherine C.
AU - Olingy, Claire E.
N1 - Funding Information:
The authors thank the members of the Hedrick laboratory for thoughtful discussions on this review. This work is supported by National Institutes of Health R01 CA202987, R01 HL134236, P01 HL136275, and U01 CA224766 (all to C.C.H.), T32 AI125279‐01, F32 HL146069‐01A1, and AHA 19POST34450020 (to L.E.P).
Publisher Copyright:
©2020 Society for Leukocyte Biology
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Monocytes and monocyte-derived cells, including Mϕs and dendritic cells, exhibit a diverse array of phenotypic states that are dictated by their surrounding microenvironment. These cells direct T cell activation and function via cues that range from being immunosuppressive to immunostimulatory. Solid tumors and atherosclerotic plaques represent two pathological niches with distinct immune microenvironments. While monocytes and their progeny possess a phenotypic spectrum found within both disease contexts, most within tumors are pro-tumoral and support evasion of host immune responses by tumor cells. In contrast, monocyte-derived cells within atherosclerotic plaques are usually pro-atherogenic, pro-inflammatory, and predominantly directed against self-antigens. Consequently, cancer immunotherapies strive to enhance the immune response against tumor antigens, whereas atherosclerosis treatments seek to dampen the immune response against lipid antigens. Insights into monocyte-T cell interactions within these niches could thus inform therapeutic strategies for two immunologically distinct diseases. Here, we review monocyte diversity, interactions between monocytes and T cells within tumor and plaque microenvironments, how certain therapies have leveraged these interactions, and novel strategies to assay such associations.
AB - Monocytes and monocyte-derived cells, including Mϕs and dendritic cells, exhibit a diverse array of phenotypic states that are dictated by their surrounding microenvironment. These cells direct T cell activation and function via cues that range from being immunosuppressive to immunostimulatory. Solid tumors and atherosclerotic plaques represent two pathological niches with distinct immune microenvironments. While monocytes and their progeny possess a phenotypic spectrum found within both disease contexts, most within tumors are pro-tumoral and support evasion of host immune responses by tumor cells. In contrast, monocyte-derived cells within atherosclerotic plaques are usually pro-atherogenic, pro-inflammatory, and predominantly directed against self-antigens. Consequently, cancer immunotherapies strive to enhance the immune response against tumor antigens, whereas atherosclerosis treatments seek to dampen the immune response against lipid antigens. Insights into monocyte-T cell interactions within these niches could thus inform therapeutic strategies for two immunologically distinct diseases. Here, we review monocyte diversity, interactions between monocytes and T cells within tumor and plaque microenvironments, how certain therapies have leveraged these interactions, and novel strategies to assay such associations.
KW - T cells
KW - atherosclerosis
KW - cancer
KW - monocytes
UR - http://www.scopus.com/inward/record.url?scp=85086342044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086342044&partnerID=8YFLogxK
U2 - 10.1002/JLB.1MIR0420-076R
DO - 10.1002/JLB.1MIR0420-076R
M3 - Review article
C2 - 32531833
AN - SCOPUS:85086342044
SN - 0741-5400
VL - 108
SP - 297
EP - 308
JO - Journal of Leukocyte Biology
JF - Journal of Leukocyte Biology
IS - 1
ER -